导 ...

前言表皮生长因子受体（EGFR）突变是非小细胞肺癌（NSCLC）最常见的驱动基因变异，以EGFR-酪氨酸激酶抑制剂（EGFR-TKI）为代表的分子靶向药物的问世为NSCLC的诊疗带来了巨大变革，开启了肺癌靶向治疗时代。目前EGFR-TKI已在临床中广 ...

We don’t need to know what cancer she had,” said one woman who spoke to Kate on Tuesday. “We just know she’s been through ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase ...

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...